Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.


TSX:EDT - Post by User

Post by TechOneon Feb 16, 2024 3:35pm
187 Views
Post# 35884915

Reverse split and US listing

Reverse split and US listing Last 3-4 years or more, at AGM time they had always asked to vote for allowing management to do a reverse and US listing..  The motion always passed except for last year when it was voted down.. 

So this year, they will probably ask again.. If there is a milestone of Baxter doing a 2nd payment as well as with new trial sites, if the enrollment picks up and if share price continues to gain, then they may have a good enough catalysts to do it.. 

My only problem with the motion was the open ended nature of 1 for 10 or 1 for 20 or 1 for xx etc. I like to see my reverse in a bit more precise terms but I guess we will see.. 

FWIW 
<< Previous
Bullboard Posts
Next >>